Westborough, MA, United States

Rxi Pharmaceuticals Corporation

www.rxipharma.com
Westborough, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Rxi Pharmaceuticals Corporation | Date: 2016-10-06

The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2-O-methyl groups at the 2nd 5-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.


Patent
Rxi Pharmaceuticals Corporation | Date: 2017-07-12

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-04-28

Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.


Aspects of the invention relate to methods for treating an ocular disorder associated with the front of the eye, comprising administering to the eye of a subject in need thereof a therapeutic RNA molecule, in an effective amount to treat an ocular disorder associated with the front of the eye.


Patent
Rxi Pharmaceuticals Corporation | Date: 2016-04-14

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.


Patent
Rxi Pharmaceuticals Corporation | Date: 2017-03-08

Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDMl), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.


Aspects of the invention relate to methods for treating an ocular disorder associated with the front of the eye, comprising administering to the eye of a subject in need thereof a therapeutic RNA molecule, in an effective amount to treat an ocular disorder associated with the front of the eye.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-06-02

The present invention relates to methods for in vivo administration of sd-rxRNA molecules.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-06-02

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.


Patent
Rxi Pharmaceuticals Corporation | Date: 2016-02-11

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

Loading Rxi Pharmaceuticals Corporation collaborators
Loading Rxi Pharmaceuticals Corporation collaborators